Vanda Pharmaceuticals Sponsors No. 47 IndyCar to Mark 47-Year Gap in Motion Sickness Treatments

Vanda Pharmaceuticals announced on Wednesday that its motion sickness treatment, NEREUS™, will serve as the primary sponsor for the No. 47 entry in the upcoming IndyCar race. The company timed the sponsorship to coincide with the 47th anniversary of the last time a new motion sickness treatment received regulatory approval in the United States.

The sponsorship marks a promotional milestone for the pharmaceutical company as it highlights the length of time since the last innovation in the motion sickness therapeutic category. By aligning the brand with the No. 47 race car, Vanda Pharmaceuticals draws a direct parallel to the 47-year gap in new treatment options for the condition. The company intends for the branding to increase visibility for NEREUS™ within the competitive landscape of the pharmaceutical market.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: July 15, 2026

Author

GOAI